doxorubicin/DNA nanocomplexes (Pharma Research/University of California/Frederick National Laboratory for Cancer Research)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namedoxorubicin/DNA nanocomplexes (Pharma Research/University of California/Frederick National Laboratory for Cancer Research)
Drug Alias Namedoxorubicin (Pharma Research/University of California/Frederick National Laboratory for Cancer Research)
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitorsVirus DNA polymerase inhibitors
TargetsTopoisomerase IIDNAVirus DNA polymerase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of California Irvine
China Registration ClassN/A

Develop Information

Active CompaniesPharmaResearch Co LtdFrederick National Laboratory For Cancer ResearchUniversity of California Irvine
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A